[HTML][HTML] Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy
C Yan, A Richmond - Molecular Cancer, 2021 - Springer
Highlights CD40 expression correlates with the type I anti-tumor response and better
survival. Pan-cancer bioinformatics characterization reveals reduced CD40 expression in 11 …
survival. Pan-cancer bioinformatics characterization reveals reduced CD40 expression in 11 …
Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy
C Yan, A Richmond - Molecular cancer, 2021 - pubmed.ncbi.nlm.nih.gov
CD40 expression correlates with the type I anti-tumor response and better survival. Pan-
cancer bioinformatics characterization reveals reduced CD40 expression in 11 cancer types …
cancer bioinformatics characterization reveals reduced CD40 expression in 11 cancer types …
[HTML][HTML] Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy
C Yan, A Richmond - Molecular Cancer, 2021 - molecular-cancer.biomedcentral …
CD40, also known as TNFRSF5, is a co-stimulatory cell surface receptor present on antigen-
presenting cells (APC), non-hematopoietic cells (eg, myofibroblasts, fibroblasts, epithelial …
presenting cells (APC), non-hematopoietic cells (eg, myofibroblasts, fibroblasts, epithelial …
Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy.
C Yan, A Richmond - Molecular Cancer, 2021 - go.gale.com
Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to
immune checkpoint blockade therapy. - Document - Gale Academic OneFile Use this link to get …
immune checkpoint blockade therapy. - Document - Gale Academic OneFile Use this link to get …
Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy.
C Yan, A Richmond - Molecular Cancer, 2021 - search.ebscohost.com
Highlights: CD40 expression correlates with the type I anti-tumor response and better
survival. Pan-cancer bioinformatics characterization reveals reduced CD40 expression in 11 …
survival. Pan-cancer bioinformatics characterization reveals reduced CD40 expression in 11 …
Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy.
C Yan, A Richmond - Molecular Cancer, 2021 - europepmc.org
CD40, also known as TNFRSF5, is a co-stimulatory cell surface receptor present on antigen-
presenting cells (APC), non-hematopoietic cells (eg, myofibroblasts, fibroblasts, epithelial …
presenting cells (APC), non-hematopoietic cells (eg, myofibroblasts, fibroblasts, epithelial …
Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy
C Yan, A Richmond - Molecular Cancer, 2021 - search.proquest.com
CD40, also known as TNFRSF5, is a co-stimulatory cell surface receptor present on antigen-
presenting cells (APC), non-hematopoietic cells (eg, myofibroblasts, fibroblasts, epithelial …
presenting cells (APC), non-hematopoietic cells (eg, myofibroblasts, fibroblasts, epithelial …
[HTML][HTML] Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy
C Yan, A Richmond - Molecular Cancer, 2021 - ncbi.nlm.nih.gov
CD40, also known as TNFRSF5, is a co-stimulatory cell surface receptor present on antigen-
presenting cells (APC), non-hematopoietic cells (eg, myofibroblasts, fibroblasts, epithelial …
presenting cells (APC), non-hematopoietic cells (eg, myofibroblasts, fibroblasts, epithelial …
[PDF][PDF] Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy
C Yan, A Richmond - 2021 - molecular-cancer.biomedcentral …
CD40, also known as TNFRSF5, is a co-stimulatory cell surface receptor present on antigen-
presenting cells (APC), non-hematopoietic cells (eg, myofibroblasts, fibroblasts, epithelial …
presenting cells (APC), non-hematopoietic cells (eg, myofibroblasts, fibroblasts, epithelial …